spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

FlyPharma Conference Europe concludes its fourth successful year in Brussels, Belgium, 5-6 June 2018

FlyPharma


The FlyPharma Conference Europe wrapped up for another year on 6 June, returning with an expanded roster of speakers who provided insight into all aspects of the pharmaceutical supply chain. The event was once again hosted at the Sheraton Brussels Airport Hotel and the Host Partner, Brussels Airport, as always provided speakers and insight into its own experiences working directly with a number of supply chain stakeholders.

FlyPharma always aims to instigate discussions on key industry topics, such as temperature excursions or security challenges, but also aims to expand attendees’ knowledge regarding newer and more unfamiliar territory, which appeared in the conference during debates over data sharing and innovative means of encouraging this, for example through blockchain technology. Behind all of these discussions was a real desire to push the industry forward and to rectify the issues that are still existent within the developing supply chain.

As in previous years, the event took place over two days (5-6 June) and featured a range of speakers from across the industry. The first day really brought into focus the impact the pharma supply chain has on people across the world, when Christine Richard, of Amerijet International Airlines, spoke on the devastation caused to Puerto Rico by Hurricane Maria that struck in September 2017, and how the company had managed to fly in pharmaceuticals despite major logistical challenges.

For many people involved, this was a life and death situation – getting in medical supplies to people was an effort of the greatest urgency. Richard explained how Amerijet, with its facilities on the island, were able to help: “As a commercial carrier, Amerijet was the first one onto the island – about 48 hours after the storm was over. We did about four to five flights per day, seven day a week, for thirteen weeks straight, bringing relief goods onto the island. After about four to five days, we started bringing in raw materials for the pharmaceutical industry so that they could start up their operations again. We also carried about 100,000 kilos of medical devices, just trying to support the pharma industry to bring out as many finished products as possible.”

This effort shows an element to the supply chain that is often not seen – its ability to react quickly to a disaster and bring about positive results, beyond any commercial interest. Efficiency of the supply chain returned again, but under a different topic, when Marrie Groeneveld, Chief Commercial Officer of SkyCell AG, highlighted just how costly temperature excursions can be to the industry.

In particular, he revealed that a conversation with a pharma company revealed it experienced 2% temperature excursions within its supply chain. This was calculated to be a €50 million cost per year for the company – not a sum of money that any company can ignore. When SkyCell pursued further research into the number of excursions experienced across the industry, the data revealed that, across 50 interviews with companies involved, they averaged at a temperature excursion rate of 8.5%. Again, demonstrating just how much work there is still to be done to secure the supply chain.

The second day saw some non-traditional solutions offered to aid the task of creating a supply chain that was both secure and transparent. One of which involved a technology that was never far from the headlines in 2017 and has seen a surge of interest in recent times: blockchain technology. Understandably, Matthew Wilson, Chief Product Officer of Veratrak, took some time to explain the basics of blockchain – when a technology has only recently come into the public consciousness, there is still a good amount of catching up to be done in terms of understanding. Wilson identified that other industries have already taken the plunge into employing blockchain, name checking Everledger, a diamond and jewellery trading platform, and Walmart, as part of its grocery goods supply chain. Though a new area of thought for the industry, there was genuine interest in learning more, which was demonstrated by the number of questions for Wilson at the end of his speech, as attendees were engaged to learn more about the potential for the technology.

At the ground level, Intelligence Manager at Sensitech, Loraine Bout, spoke on the dangers of pharmaceutical theft – despite this only representing 1% of thefts by product type. Bout emphasised that this is only reported data and that theft it highly underreported; there is also a tendency to downplay the facts, making it difficult to truly assess cost.

More fundamentally, a supply chain’s success or failure can sometimes come from the individuals directly involved in the transportation of the goods: the people on the ground at the end of the chain, or the truck drivers. Gerton Hulsman, Managing Director of DUS Airport Cargo, contributed a thought from the audience that it is the responsibility of all members of the supply chain to ensure that these individuals are adequately treated and fairly paid to ensure that they too have a stake in the security of the supply chain, a comment that drew approbation from across the room.

The audience insight that drew the greatest applause during the event came from Steven Polmans, Head of Cargo & Logistics at Brussels Airport Company. He recounted, during the setting up of the IATA CEIV Pharma certification, how there had been some doubt from a number of companies about the importance of achieving accreditation: “Until one gentlemen stood up, I still thank you for this Eddy [Eddy Weygaerts, Senior Manager for Logistics Delivery ELC & ES EU for Pfizer], and said to the whole of the room: ‘If you do not do this and if you do not change, then you’re not going to have my cargo in future and that is what is going to happen.’ By the end of meeting, we had our ten companies to launch because suddenly everyone was interested. So, if tomorrow the shippers would sit together and then say, ‘this is the standard’, you would be surprised by how quickly we can move as an industry”.

The reason the response drew such a strong reaction is due to the understanding that the supply chain is able, when encouraged, to rise successfully to whatever new challenges it is faced with. It was indicative of the sense of positivity and energy that all stakeholders have in the industry to move forward, and quickly, to secure the pharma supply chain.

If you would like to participate in future discussions and learn from a select group of speakers and audience members, make sure to visit www.FlyPharmaConference.com for information about FlyPharma’s upcoming events. This now includes FlyPharma US, launching its inaugural event in Miami on 11-12 September 2018, and FlyPharma Asia, which will take place for the second year in Hong Kong on 9-10 April 2019.

FlyPharma Europe returns to Brussels for its fifth event on 4-5 June 2019, so visit the website now to secure your place at the next event. If you have any questions or wish to learn more about FlyPharma conferences, including your potential for being involved, please contact Angela Cottrell, Events Director (angela@samedanltd.com) or Rhian Goldsbrough, Events and Marketing Assistant (rhian@samedanltd.com).
email flypharma@samedanltd.com
web www.FlyPharmaEurope.com
 
Print this page
Send to a friend
   
spacer
News and Press Releases

BioIVT Webinar Will Discuss How to Optimize Microbiome Research

BioIVT, a leading provider of research models and services for drug development, today announced that it is hosting a webinar entitled “The Microbiome: Understanding Why Collection and Processing Matters” at 11 a.m. ET on July 25.
More info >>


White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

Industry Events

SCOPE Europe: Summit for Clinical Ops Executives

16-17 October 2018, Barcelona, Spain

Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clin ops execs, functional heads, category managers and those responsible for the planning and management of clinical trials in Europe and the Rest of the World.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement